Follow the latest news on emerging brain tumour treatments with commentary from a 10+ year survivor of a high grade glioma. News features on metabolic treatments and novel therapies will be prioritised.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 135 | Founded | 4 years ago | Last Issue | 4 days ago |
| Active | |||||
Read this Newsletter
andrewscarborough.substack.comLatest Issues
Promising treatments, closed doors and gatekeepers.
In brain cancer, especially glioblastoma, the Stupp protocol is often called the “gold standard”. For the few who may not know, this is the radiotherapy with concurrent and then maintenance temozolomide regimen that we’ve become all too fam...
A Closer Look at DCVax-L
This week, thanks to Northwest Biotherapeutics, I had the privilege of visiting Advent BioServices in Cambridge. I was joined by a small but incredible group of people, including scientists, patient advocates and representatives from Brain...
I tested my tap water. Here’s what I found.
Some surprising results, but there's still more I need to know.
As you may be aware, I recently had my tap water independently tested by IVARIO. You can read more about the testing process and why I decided to do this in my article from a...
Highlights from EANO 2026
A memorable conference in Rome
Last week I travelled to Rome for the European Association of Neuro-Oncology’s annual conference. This is one of my favourite meetings to attend because I always learn something new from experts in the field...
A different kind of cancer conference
Day 1 at the first National Centre for Integrative Oncology conference at the University of Oxford
Over the weekend I travelled to Oxford for something a little different: the first annual conference of the National Centre for Integrative...
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Andrew’s Substack.
| Subscribers | Engagement | 69 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Long term brain cancer survivor, writer, researcher. Interest in metabolic therapies. Follow @cancermetstudy for more info.
Social
Frequently Asked Questions
How can I access the email archive for Andrew’s Substack?
You can find recent issues that have been published by Andrew’s Substack on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Andrew’s Substack have?
To see how many people subscribe to Andrew’s Substack, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Andrew’s Substack?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Andrew’s Substack as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Andrew’s Substack?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Andrew’s Substack using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Andrew’s Substack?
Scroll up to where it says Related Newsletters to see other publications like Andrew’s Substack. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Andrew’s Substack?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.